Budget impact analysis of the treatment of chronic hepatitis C in a hospital;Análisis de impacto presupuestario en el tratamiento de la hepatitis por virus C en un hospital

Farmacia Hospitalaria

Volumn 30, Issue 5, 2006, Pages 291-299

  Casado Gómez, Miguel Ángel ^a   Alvarez Rubio S ^b   Miro Manero ^b   Marino Hernandez E L ^c   Buti Ferret, M ^d  

^a Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Budget impact analysis; Chronic hepatitis C; Pegylated interferons; Ribavirin

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; BUDGET; CONTROLLED STUDY; DRUG COST; FINANCIAL MANAGEMENT; HEPATITIS C; HOSPITAL MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; TREATMENT DURATION; TREATMENT WITHDRAWAL;

EID: 33846227850     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(06)73993-9     Document Type: Article

References (30)

1. EASL International Consensus Conference on Hepatitis C. Paris, 26-28 February 1999. J Hepatol 1999; 30: 956-61.
2. National Institute of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002- June 10-12, 2002. Hepatology 2002; 36 (Supl.1): S3-20.
3. Buti M, Casado MA, Fosbrook L, Esteban R. Financial impact of two different ways of evaluating early virological response to peginterferon alfa-2b plus ribavirin therapy in genotype 1 naïve patients with chronic hepatitis C. Pharmacoeconomics 2005; 23: 1043-55.
4. Buti M, Sanmiguel R, Brosa M, Cabasés JM, Medina, M, Casado MA, et al. Estimating the impact of hepatitis C virus therapy on the future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42: 639-45.
5. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naïve patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 687-94.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
8. Chambers M, Hutton J, Nuitjen M. Budget impact analysis for health technology appraisal: development and application within the NICE appraisal process. J Clin Excellence 2002; 4: 203-6.
9. Gagni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomis 2003; 21: 149-57.
10. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001; 19: 855-67.
11. Orlewska E, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to exisiting guidance on budget impact in other countries. Value in Health 2004; 7; 1-10.
12. Brosa M, Gisbert R, Rodríguez JM, Soto J. Principios, métodos y aplicaciones del análisis del impacto presupuestario en el sector sanitario. Pharmacoeconomics - Spanish Research Articles 2005; 2: 64-78.
13. European Medicines Agency. EMEA released template for EU risk-management plans. Published in October, 10, 2006. Available at: http://www.emea.eu.int/
14. Consejo General de Colegios Oficiales de Farmacéuticos de España. Catálogo de Especialidades Farmacéuticas. Colección Consejo Plus; 2005.
15. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21: 89-103.
16. Darba J. Pharmaceutical expenditure and therapeutic value of new medicines in Spain. Pharmacoeconomics 2003; 21: 1211-2.
17. Wang Z, Salmon JW, Walton SM. Cost-effectiveness analysis and the formulary decision-making process. J Manag Care Pharm 2004; 10: 48-59.
18. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
19. Craxi A. Early virologic response with pegylated interferons. Dig Liver Dis 2004; 36 (Supl. 3): S339-42.
20. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-32.
21. Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22: 257-65.
22. Shepherd J, Brodin HF, Cave CB, Waugh NR, Price A, Gabbay J. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care 2005; 21:47-54.
23. Soto J, Sacristán JA, Galende I. Estudios naturalísticos para valorar la efectividad de los medicamentos tras su comercialización: ¿por qué, cuándo y cómo? Aten Prim 1998; 22: 182-5.
24. Nuitjen MJC, Rutten F. Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques. Pharmacoeconomics 2002; 20: 855-67.
25. Anis AH, Gagnon Y. Using pharmacoeconomic analysis to make drag insurance coverage decisions. Pharmacoeconomics 1998; 13: 119-26.
26. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
27. Nuijten MJC, Kosa J, Engelfriet P. Modeling the cost-effectiveness and budgetary impact for subpopulations. Eur J Health Econom 2003; 4: 70-8.
28. Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK; International Hepatitis Interventional Therapy Group. Economic and Clinical Effects of Evaluating Rapid Viral Response to Peginterferon Alfa-2b plus Ribavirin for the Initial Treatment of Chronic Hepatitis C. Am J Gastroenterol 2003; 98: 2354-62.
29. D'Souza R, Main J, Crossey M, Rosenberg W, Murray-Lyon IM, Hayward C, et al. Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy - patients' views of early cessation of therapy. Aliment Pharmacol Ther 2005; 21: 43-7.
30. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained virologic response in genotype 1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.